Predictions
Zoetis Inc. A
Start price
Target price
Perf. (%)
€176.92
03.08.22
03.08.22
€190.00
03.08.23
03.08.23
-6.34%
03.08.23
03.08.23
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Future proof or reliable business model
Inovio Pharma
Start price
Target price
Perf. (%)
€2.12
03.08.22
03.08.22
€2.60
03.08.23
03.08.23
-11.19%
20.09.22
20.09.22
Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.39
03.08.22
03.08.22
€2.80
03.08.23
03.08.23
-14.19%
20.09.22
20.09.22
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Canopy Growth Corp
Start price
Target price
Perf. (%)
€2.91
03.08.22
03.08.22
€3.30
03.08.23
03.08.23
-12.37%
13.10.22
13.10.22
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
Pfizer Inc.
Start price
Target price
Perf. (%)
€49.24
31.07.22
31.07.22
€50.00
31.07.23
31.07.23
-31.05%
22.05.23
22.05.23
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
EssilorLuxottica SA
Start price
Target price
Perf. (%)
€157.25
29.07.22
29.07.22
€200.00
29.07.23
29.07.23
14.87%
30.07.23
30.07.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
Nanorepro AG
Start price
Target price
Perf. (%)
€3.97
27.07.22
27.07.22
€15.00
27.08.22
27.08.22
-14.12%
28.08.22
28.08.22
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Very high dividend yield expected
Top 10 in its market
Medtronic plc
Start price
Target price
Perf. (%)
€91.39
27.07.22
27.07.22
€100.00
27.07.23
27.07.23
-11.48%
28.07.23
28.07.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
Fresenius Medical Care AG & Co KGaA ST
Start price
Target price
Perf. (%)
€44.85
27.07.22
27.07.22
€60.00
27.07.23
27.07.23
5.35%
27.07.23
27.07.23
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Innovative
High dividend yield expected
Stratec SE
Start price
Target price
Perf. (%)
€85.00
26.07.22
26.07.22
€66.00
26.07.23
26.07.23
4.94%
06.08.22
06.08.22
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
US Physical Therapy Inc.
Start price
Target price
Perf. (%)
€122.00
26.07.22
26.07.22
-
26.07.23
26.07.23
-9.84%
26.07.23
26.07.23
Tonix Pharmaceuticals Holding Corp.
Start price
Target price
Perf. (%)
€8.56
25.07.22
25.07.22
€12.50
25.07.23
25.07.23
26.95%
26.07.22
26.07.22
Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Little innovation
Kezar Life Sciences
Start price
Target price
Perf. (%)
€9.55
25.07.22
25.07.22
€20.00
31.12.24
31.12.24
-75.71%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
EssilorLuxottica SA
Start price
Target price
Perf. (%)
€154.40
23.07.22
23.07.22
€170.00
23.08.22
23.08.22
5.63%
11.08.22
11.08.22
Could be very worthwhile Investment >20% year
Innovative
Sustainability is important
Small cyclical dependencies
Sartorius AG VZO
Start price
Target price
Perf. (%)
€418.20
22.07.22
22.07.22
€550.00
22.07.23
22.07.23
-23.00%
30.05.23
30.05.23
Valneva SE
Start price
Target price
Perf. (%)
€9.82
21.07.22
21.07.22
-
21.07.23
21.07.23
-30.16%
22.07.23
22.07.23
Revenue growth >5% per year expected
Could be very worthwhile Investment >20% year
High valuation
Growths slower than the competition
Promis Neurosciences Inc.
Start price
Target price
Perf. (%)
€5.37
21.07.22
21.07.22
€5.30
21.07.23
21.07.23
-21.42%
11.03.23
11.03.23
ROE lower than 10% per year
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
CytoDyn Inc_INT
Start price
Target price
Perf. (%)
€0.65
21.07.22
21.07.22
€0.60
21.07.23
21.07.23
-46.97%
19.11.22
19.11.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
Pfizer Inc.
Start price
Target price
Perf. (%)
€49.74
20.07.22
20.07.22
€55.00
20.07.23
20.07.23
-33.55%
21.07.23
21.07.23
Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
Clovis Oncology Inc.
Start price
Target price
Perf. (%)
€1.87
18.07.22
18.07.22
-
18.07.23
18.07.23
-9.48%
23.07.22
23.07.22
Could be worthwhile Investment >10% per year